60
Participants
Start Date
July 17, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
SPH5030
SPH5030：Oral, QD, 600mg
RECRUITING
Beijing Friendship Hospital，Capital Medical University, Beijing
RECRUITING
Chinese PLA General hospital, Beijing
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
The Second Affiliatedf Hospital of AFMU, Beijing
RECRUITING
XiangYa Hospital CentralSouth University, Changsha
RECRUITING
Changzhi People's Hospital, Changzhi
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
General Hospital of Fuzhou, Fuzhou
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
RECRUITING
Hengshui People's Hospital, Hengshui
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Shanghai General Hospital, Shanghai
RECRUITING
The Third Affiliated Hospital of Air Force Medical University, Shanghai
RECRUITING
Zhongshan Hospital, Shanghai
RECRUITING
Shantou University Medical College Cancer Hospital, Shantou
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
Shanxi Cancer Hospital, Taiyuan
RECRUITING
Tianjin Medical University Cancer institute & Hospital, Tianjin
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Affiliated Hospital of Jiangnan University, Wuxi
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Xiangyang Central Hospital, Xiangyang
RECRUITING
Yantai Yuhuangding Hospital, Yantai
RECRUITING
Henan Cancer Hospital, Zhengzhou
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY